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Abstract: LONP1 is a nuclear-encoded mitochondrial protease crucial for organelle homeostasis;
mutations of LONP1 have been associated with Cerebral, Ocular, Dental, Auricular, and Skeletal
anomalies (CODAS) syndrome. To clarify the role of LONP1 in vivo, we generated a mouse model in
which Lonp1 was ablated. The homozygous Lonp−/− mouse was not vital, while the heterozygous
Lonp1wt/− showed similar growth rate, weight, length, life-span and histologic features as wild type.
Conversely, ultrastructural analysis of heterozygous enterocytes evidenced profound morphological
alterations of mitochondria, which appeared increased in number, swollen and larger, with a lower
complexity. Embryonic fibroblasts (MEFs) from Lonp1wt/− mice showed a reduced expression of Lonp1
and Tfam, whose expression is regulated by LONP1. Mitochondrial DNA was also reduced, and
mitochondria were swollen and larger, albeit at a lesser extent than enterocytes, with a perinuclear
distribution. From the functional point of view, mitochondria from heterozygous MEF showed a
lower oxygen consumption rate in basal conditions, either in the presence of glucose or galactose,
and a reduced expression of mitochondrial complexes than wild type. In conclusion, the presence
of one functional copy of the Lonp1 gene leads to impairment of mitochondrial ultrastructure and
functions in vivo.
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1. Introduction
LONP1 protease is a nuclear-encoded protein located in the mitochondrial matrix, belonging
to the ATPase associated with diverse cellular activities (AAA+) superfamily [1]. LONP1 is highly
conserved throughout evolution from archea to mammals and it is ubiquitously expressed in different
cells and tissues [2–4].
LONP1 is composed of three domains: the N terminus interacts with the substrates, the AAA+
domain binds and hydrolyzes ATP and the P terminus contains the proteolytic active site [5–7].
The main function of LONP1 is to degrade misfolded, oxidized and damaged proteins but it also
actively participates in other mitochondrial functions, modulating the amount of protein involved in
mitochondrial structure and mtDNA maintenance such as the Mitochondrial transcription factor A
(TFAM) [8–11]. Protein degradation mediated by LONP1 can modulate the respiratory process [12,13]
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and the energetic metabolism [8,14]. LONP1 is a stress response protein, as its level increases
in the presence of hypoxia, reactive oxygen species (ROS) and reticulum endoplasmic (ER)-stress,
and its down-regulation impairs response to stress and alters mitochondrial morphology [14–20].
Finally, LONP1 displays chaperon activity and is required for maturation of several mitochondrial
proteins [12,21].
Modified amounts and activity of LONP1 are associated with several diseases such as mitochondrial
encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), myoclonic epilepsy with
ragged-red fibers (MERRFs), hereditary spastic paraplegia, Friedrich ataxia, hereditary paraganglioma
and Highly Active Antiretroviral Therapy (HAART) related lipodystrophy [22–27]. LONP1 is
upregulated in different types of cancer, and its upregulation makes cancer cells resistant to new
environmental conditions, such as hypoxia, typical of malignant tumors [8,28–33].
Heterozygous and compound heterozygous mutations in AAA+ and proteolytic domains of
the LONP1 gene are linked to cerebral, ocular, dental, auricular, and skeletal anomalies syndrome
(CODAS; MIM 600373), a rare recessive disorder diagnosed in 19 cases since its first description
in 1991 [34–39]. CODAS is characterized by several congenital anomalies including short stature,
ossification of epiphyseal and developmental delay, coronal clefts, dislocated hips, and craniofacial
defects (median nasal groove, ptosis, bilateral early onset cataracts, anomalous ears and hearing loss,
abnormal cusp morphology and delayed tooth eruption). The disease has a severe impact on the life
of the affected patients, leading in some cases to premature death [39]. Skeletal abnormalities and
cataracts are pathognomonic of CODAS, whereas other anomalies are in common with mitochondrial
diseases [39,40]. Other biallelic variants in LONP1 gene do not cause CODAS, but determine profound
neurodegeneration with progressive cerebellar atrophy, associated with pyruvate dehydrogenase
deficiency and metabolic disfunctions [41], or classical mitochondrial diseases, such as Leigh disease [40].
Deficiency of LONP1 has been studied in a mouse model, and it has been demonstrated that
homozygous deletion of this gene is embryonically lethal, because of a progressive loss of mtDNA which
finally leads to the death of fetus at 7.5 days post coitum. The heterozygous Lonp1wt/− mouse is viable
and fertile, but this model has only partially been characterized [32], showing that haploinsufficiency of
Lonp1 abrogates ischemic preconditioning cardio-protection [42]; the analysis of the proteome of mouse
embryonic fibroblasts (MEFs) suggests that the Lonp1wt/− genotype determines enhanced respiratory
dysfunction [43].
We have previously shown that LONP1 downregulation determines a severe impairment of
mitochondrial morphology and functionality in colon cancer cells, and that this impacts on epithelial
mesenchymal transition in colon cancer. Thus, in this study we generated and characterized a
heterozygous Lonp1wt/- mouse model, focusing our attention of the effects of Lonp1 haploinsufficiency
on mitochondria morphology and function of colon enterocytes, and on the functional effects on
mitochondria of MEFs.
2. Materials and Methods
2.1. Generation and Genotyping of Lonp1wt/− Mice
The Lonp1wt/− mouse (background C57BL/6) was provided by Biogem Srl (Ariano Irpino, Italy) by
generating a knock-out allele encompassing exons 5 and 8 (Figure S1). Genotyping was performed
by polymerase chain reaction (PCR) on 20–50 ng of genomic DNA obtained from ear samples using
the commercial Easy-DNA™ gDNA Purification Kit (Thermo Fisher Scientific, Waltham, MA, USA)
amplified in 25 µL of reaction mixture having this composition: 1X GoTaq Flexy Buffer (Promega
Corporation, Madison, WI, USA), 2 mM MgCl2, 0.2 mM of each dNTP (Promega Corporation), 0.03 U
of GoTaq G2 Flexy DNA Polymerase and 0.2 µM of each primer. The cycling parameter protocol
included an initial step of denaturation at 95 ◦C for 1 min followed by: 2 cycles at 95 ◦C 15 s, 64 ◦C
15 s, 72 ◦C 1 min; 2 cycles at 95 ◦C 15 s, 61 ◦C 15 s, 72 ◦C 1 min; 20 cycles at 95 ◦C 15 s, 58 ◦C
15 s, 72 ◦C 1 min; 10 cycles at 95 ◦C 15 s, 55 ◦C 15 s, 72 ◦C 1 min and a final extension step at
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72 ◦C for 10 min. The following primers were used: forward 5′-cagggaagaaactgaagtcaggc-3′, reverse
5′-cactctggttcatggccacc-3′, producing a 925 bp product only for knock-out allele, detected by agarose
gel electrophoresis.
2.2. Ethics Statement
All animal procedures were approved in accordance with Italian law protecting animals used for
scientific purposes (authorization n◦253/2017-PR, released on 21st March 2017 by the Italian Ministry
of Health).
2.3. Isolation of Organs and Tissue
Mice were subjected to euthanasia and sacrifice by cervical dislocation, then placed on their back
on a thick pad of blotting paper. After soaking fur in 70% ethanol, skin was cut with scissors and the
organs of interest were explanted and analyzed for any morphological variation, then weighed and
measured for dimensions. Heads and red organs were harvested from embryos during the isolation of
MEFs. Finally, all the tissues were stored in liquid nitrogen or treated for subsequent applications.
2.4. Isolation and Culture of MEFs
Mouse embryos at 12.5 to 15.5 days post coitum were harvested from a pregnant female and
dissected into sterile phosphate buffered saline (PBS) added with Penicillin/Streptomycin (10,000 U/mL;
Thermo Fisher Scientific). After the removal of the visible internal organs and of the head, the carcasses
were minced using a scalpel and digested with 0.25% trypsin-EDTA (Thermo Fisher Scientific) added
with Penicillin/Streptomycin at 37 ◦C for 20 min. The obtained cell suspensions were transferred
into 25 cm2 flasks and cultured in Dulbecco’s Modified Eagle Medium (DMEM) Glutamax (Thermo
Fisher Scientific) supplemented with 10% fetal bovine serum (FBS; Thermo Fisher Scientific) and
Penicillin/Streptomycin. After the confluence, MEFs were grown in 75 cm2 flasks and used in
experiments at 5th passage. The galactose medium used in bioenergetics experiments is composed
of DMEM without glucose (Thermo Fisher Scientific) supplemented with 10% FBS, 5 mM galactose,
5 mM pyruvate and Penicillin/Streptomycin. Cells have been grown in galactose medium for 9 days.
2.5. Quantification of Mitochondrial DNA
Total DNA was isolated from 25 mg of fresh or stored tissue by using QIAamp® DNA Mini Kit
(QIAGEN, Hilden, Germany) following manufacturer’s instructions. Amount of DNA was measured
using the NanoDrop ND-1000 (Thermo Fisher Scientific) and samples were diluted to 50 ng/µL.
The amount of mtDNA was quantified by real-time in tissues and by droplet digital PCR (ddPCR)
in MEFs. Real time PCR was carried out on CFX96 Touch™ Real-Time PCR Detection System (Bio-Rad
Laboratories, Hercules, CA, USA) and the reaction mixture had this composition in 10µL of final volume:
1 µL of DNA samples, 1X SsoAdvanced universal SYBR® Green super-mix (Bio-Rad Laboratories) and
15 pM of each primer. The thermal protocol includes an initial step of polymerase activation and DNA
denaturation at 95 ◦C for 2 min, followed by 40 cycles of denaturation at 95 ◦C 5 s, annealing/extension
and plate read at 60 ◦C 20 s; after, a melting curve with 0.5 ◦C increment 5 s/step between 65 ◦C
and 95 ◦C was determinate. mtDNA amount was normalized to Tubulin, as relative quantification.
The following primers were used: Tubulin forward: 5′-GCCAGAGTGGTGCAGGAATA-3′, Tubulin
reverse: 5′-TCACCACGTCCAGGACAGAGT-3′, mtDNA forward: 5′-CATTTGCAGACGCCATAA-3′,
mtDNA reverse; 5′-TGGGTGTGGTATTGGTAGGG-3′. For every point and every group of the
investigation, tissues belonging to three mice were evaluated and cycle threshold (Ct) values were used
to calculate the ∆Ct between mtDNA and the control gene and used to calculate the mtDNA amount.
The reaction mixture of ddPCR in 20 µL of final volume is composed of: 20 ng of DNA samples, 2X
ddPCR Supermix for Probes (Bio-Rad Laboratories), 1 µL of PrimePCR™ ddPCR™ Expression Probe
Assay mt-Nd1 (FAM fluorescence), 1 µL of PrimePCR™ ddPCR™ Expression Probe Assay Tubb2b
(HEX fluorescence). Thermal cycling conditions are: 95 ◦C for 10 min, followed by 38 cycles of 94 ◦C
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for 30 s and 55 ◦C for 1 min, then 98 ◦C for 10 min. Droplet reading is performed on QX200 ddPCR
droplet reader (Bio-Rad laboratories). Analysis are performed using QuantaSoft Analysis software
(version 1.7.4.0917, Bio-Rad laboratories).
2.6. Immunoblot
Total cellular and tissue proteins were obtained by lysing cells and homogenizing tissues with
RIPA buffer (50 mM Tris, pH 7.5, 0.1% Nonidet P-40, 0.1% deoxycholate, 150 mM NaCl, 4 mM EDTA,
and protease inhibitors cocktail). The tissues were maintained in ice and homogenized for ~5 min
until they were fully dissociated, while cellular pellets were dissociated using syringe and needles.
Samples were kept in ice for 30 min, and then they were centrifuged at 15,000× g for 30 min at 4 ◦C.
Proteins were quantified by Bradford assay (Bio-Rad Laboratories). Samples (30–50 µg) were separated
in 4–12% Bolt Bis-Tris precast gels (Thermo Fisher Scientific) and transferred onto nitrocellulose or
polyvinylidene fluoride (PVDF, for OXPHOS complexes) membranes (Bio-Rad Laboratories) by using
methanol transfer buffer. After blocking with 5% Blotting-Grade Blocker (Bio-Rad Laboratories),
the membranes were incubated with the following primary antibodies: custom anti-LonP1 (1:500)
from Primm (Milan, Italy), anti-TFAM (1:2000; Abnova Corporation, Taipei, Taiwan), anti-OXPHOS
complexes (1:250; Abcam, Cambridge, UK) anti-α-Tubulin (1:1000; Sigma-Aldrich, Saint Louis, MO,
USA), anti-ACO2 (1:1000; Abnova Corporation), anti-GRP75 (1:500; Santa-Cruz Technologies, Dallas,
TX, USA), anti-SOD2 (1:500; Abcam), anti-TOM20 (1:500; Santa-Cruz Technologies) and then washed
and incubated with the secondary antibodies Goat Anti-Mouse IgG (H + L)-HRP Conjugate and
Goat Anti-Rabbit IgG (H + L)-HRP Conjugate (1:5000; Bio-Rad Laboratories). Peroxidase activity
was detected using Clarity™ Western ECL Blotting Substrates (Bio-Rad Laboratories). Images were
acquired by using ChemiDoc MP (Bio-Rad Laboratories). The densitometric analysis was performed
with Image Lab (version 6.1, Bio-Rad Laboratories). Bands were automatically detected using the “Lane
and Bands” tool, and the band intensities analyzed with Prism 8.0 (GraphPad Software, San Diego,
CA, USA).
2.7. Hematoxylin and Eosin Staining
After explant, the tissues were washed with PBS, fixed with 4% paraformaldehyde in PBS for ~2 h
and embedded in paraffin. Serial cross-sections were cut and then mounted onto slides. Hematoxylin
and eosin (H&E) staining was performed on sections of 5 µm in order to analyze the morphological
details of the tissues.
2.8. Confocal and Stimulated Emission Depletion (STED) Microscopy
MEF samples were seeded at 3 × 105 cells/well in 6-well plates on glass coverslips, and fixed with
4% paraformaldehyde for 10 min. After fixation, cells were permeabilized with 0.1% Triton X-100 in
PBS for 5 min and blocked with 3% bovine serum albumin (BSA) in PBS for 30 min, at room temperature.
Incubation with primary antibodies were performed for 1 h at room temperature. After washing
with 3% BSA in PBS, samples were incubated for 1 h at room temperature with secondary antibodies.
Samples were then washed in PBS and stained with 0.5 µg/mL 4,6-diamidino-2-phenylindole (DAPI)
(Sigma-Aldrich) in PBS for 5 min, washed again in PBS and mounted. Samples prepared for STED
microscopy were not incubated with DAPI. Cells were observed and images were acquired at Leica
TCS SP8 confocal laser scanning microscope (Leica Microsystems, Wetzlar, Germany). STED images
were obtained by using a Leica TCS SP8 microscope (Leica Microsystems) equipped with a HC PL
APO 100x/1.40 OIL, a white light laser (470–650 nm), STED 3X, FLIM, a 775 nm pulsed depletion laser
and hybrid detectors. The following antibodies were used: anti-LonP1 (1:100; Primm), anti-TOM20
(1:50; Santa-Cruz Technologies), anti-dsDNA (1:100; Santa Cruz Technologies), goat anti-rabbit Alexa
Fluor 488 (1:200; Thermo Fisher Scientific), goat anti-mouse Alexa Fluor 488 (1:200; Thermo Fisher
Scientific), goat anti-mouse Alexa Fluor 546 (1:200; Thermo Fisher Scientific), Goat anti-Rabbit IgG (H +
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L) Alexa Fluor 647, Goat anti-mouse Alexa Fluor 594 (1:500; Thermo Fisher Scientific), goat anti-rabbit
ATTO 647N (1:500; Abcam).
2.9. Electron Microscopy
Colon and cell pellet were processed as described previously with some modifications [44]. Briefly,
samples were chemically fixed in a solution of 2.5% glutaraldehyde (Electron Microscopy Sciences)
dissolved in 0.1 M cacodylate buffer at pH 7.4 for 12 h. Post fixation was performed for 1 h in 1%
OsO4 using the same buffer. The specimens were dehydrated with ethanol in concentrations increasing
to 100% and embedded in Epson 812 (Electron Microscopy Sciences, Hatfield, PA, USA). The resin
polymerization was carried out at 60 ◦C for 2 days. Ultrathin sections (60–70 nm) were cut and mounted
on 150-mesh copper grids and stained with UranyLess (Electron Microscopy Sciences) followed by
lead citrate. Sections were observed with a FEI NOVA NanoSEM 450.
2.10. Morphological Analysis of Mitochondria
Morphological measurement of mitochondria was obtained using ImageJ (version 1.52p, National
Institutes of Health, USA). Distinct mitochondria were manually traced on electron microscopy images
of colon of adult mice and MEFs and the following parameters were analyzed: mitochondrial size;
perimeter; aspect ratio (AR, length-to-width ratio) as [(major axis)/(minor axis)]; form factor (FF,
reflecting the complexity aspect of mitochondria) as [(perimeter2)/(4pi·surface area)].
2.11. Oxygen Consumption Rate (OCR) and Extracellular Acidification Rate (ECAR)
XFp Extracellular Flux Analyzer (Seahorse Biosciences—Agilent Technologies, Santa Clara, CA,
USA) was used to assay OCR and ECAR. Cells were plated in number of 2 × 104 cells/well 1 day
before the experiment, and experiments were performed on a confluent monolayer. Measurements
were performed under basal conditions and then after injections of oligomycin (1.0 µM), carbonyl
cyanide 4-trifluoromethoxy-phenylhydrazone (FCCP, 1.0 µM), rotenone and antimycin A (0.5 µM of
both). Data have been normalized to sample protein concentrations, following instructions provided
by the manufacturer.
2.12. Cytofluorimetric Analyses
Flow cytometry was used to determine mitochondrial membrane potential (MMP), and
mitochondrial superoxide production. For MMP, cells were incubated with tetramethyl-rhodamine,
methyl ester (TMRM, 100 nM, Thermo Fisher Scientific) for 30 min at 37 ◦C, and valinomycin (10 µM,
Sigma Aldrich) for 15 min at 37 ◦C was used to induce mitochondrial membrane depolarization.
Mitochondrial superoxide production was assessed using MitoSox Red Mitochondrial Superoxide
Indicator (mtSOX, 5 µM, Thermo Fisher Scientific) for 30 min at 37 ◦C and H2O2 (2 mM, Sigma
Aldrich) for 30 min at 37 ◦C as positive control. Then, cells were analyzed by flow cytometry using an
Attune NxT (Thermo Fisher Scientific). The net median fluorescence intensity (MFI) was analyzed
subtracting the MFI of the unstained samples to the MFI of the stained samples to prevent the influence
of autofluorescence. Finally, the net MFI value of a wild type (wt) sample was set to 100 and other
samples were determined as relative MFI level according to the formula: (heterozygous (het) sample
net MFI/wt sample net MFI) × 100. Data were analyzed with FlowJo software (version 9.9.6, Tree Star,
Ashland, OR, USA).
2.13. Statistical Analysis
Statistical analyses were performed using Prism 8.0 (GraphPad Software). The results are
expressed as the mean ± SEM. Non-parametric Mann-Whitney test was used to compare quantitative
variables. p value < 0.05 was considered significant.
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3. Results
3.1. Lonp1 Depletion Causes Early Embryonic Lethality
We previously observed that LONP1 silencing causes cell death in vitro in colon carcinoma cells [8].
To obtain more insight on the role of Lonp1 downregulation in vivo, we generated a mouse model in
which Lonp1 gene was ablated; we deleted the exons 5–8 of the gene, which encode the domains with
ATPase and proteolytic activity. We first obtained a heterozygous mouse (Lonp1wt/−) for the targeted
allele of Lonp1, which was viable and fertile. When intermated, we did not obtain any KO mouse
(Lonp1−/−) pups at birth, confirming the previously observed early embryonic lethality of the depletion
of Lonp1 [32]. Thus, we focused our attention on the characterization of the heterozygous mouse.
3.2. Phenotypic Characterization of the Lonp1wt/− Mouse
We first characterized the Lonp1wt/− mouse from the phenotypic point of view. We explored the
distribution of animals and litters among different types of mating. The analysis included 51 litters,
for a total of 229 animals, in particular: 27 litters (110 animals) from Lonp1wt/− × Lonp1wt/− mating, 13
litters (67 animals) from Lonp1wt/− ♂× Lonp1wt/wt ♀mating and 11 litters (52 animals) from Lonp1wt/wt
× Lonp1wt/− mating (Table 1). We analyzed the distribution of sex of the wt and heterozygous (het)
animals in the litters, finding that animals were born at the expected Mendelian ratio, whatever the
genotype of parents were (Table 2). The distribution of the number of pups born and the duration of
pregnancy was similar for all the considered mating types (not shown).
Weight and length of mice body were similar for wt and het mouse at any age considered
(Figure 1A); no difference was noted when we compared only males or females. To gain more insight at
organ level, we additionally analyzed the weight of different organs and tissues (spleen, heart, vastus,
gastrocnemius, soleus, biceps, brain, liver) in young (2 months old) and adult (8 months old) animals.
As shown in Figure 1B, we did not detect any genotype-dependent difference.
Taken together, these data demonstrated that no gross phenotypic abnormalities could be observed
in Lonp1wt/− mice.
3.3. LONP1 and mtDNA Levels in Wild Type and Lonp1wt/− Mice
We next quantified expression of LONP1 protein in the same organs and tissues analyzed for
the phenotypic characterization of het mouse; the analysis was performed in young (2 months old)
and adult (8 months old) mice (Figure 2A,B and Figure S2). The expression of LONP1 is considerably
variable among tissues, both in wt and Lonp1wt/− mice, with the highest levels observed in liver and
spleen of young mice, and a lower but similar level observed in different muscles, colon, rectum, heart,
cerebellum and brain. These levels were roughly maintained during aging, with the notable exception
of the spleen, whose high levels in young mice tended to decline with age, and colon, whose level
increases with age. Heterozygous mice expressed approximately the same amount of LONP1 protein
as wt in most of the tissues and organs considered, with the exception of colon and heart of adult mice,
in which LONP1 showed a significant reduction (53% and 45% respectively).
Table 1. Distribution of offspring in different type of mating according to sex. − indicates targeted
Lonp1 allele.
Male Female
Type of Mating Total Born Expected Born Expected
wt/− ♂x wt/− ♀ 110.0 58.0 55.0 52.0 55.0
wt/− ♂x wt/wt ♀ 67.0 36.0 33.5 31.0 33.5
wt/wt ♂x wt/− ♀ 52.0 27.0 26.0 25.0 26.0
Total 229.0 121.0 114.5 108.0 114.5
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Table 2. Distribution of offspring in different type of mating according to Lonp1 genotype. − indicates targeted Lonp1 allele.
Total Male Female
Wild Type Heterozygous Wild Type Heterozygous Wild Type Heterozygous
Type of mating Total Born Expected Born Expected Born Expected Born Expected Born Expected Born Expected
wt/− ♂x wt/− ♀ 110.0 45.0 36.7 65.0 73.3 24.0 19.3 34.0 38.7 21.0 17.3 31.0 34.7
wt/− ♂x wt/wt ♀ 67.0 33.0 33.5 34.0 33.5 21.0 18.0 15.0 18.0 12.0 15.5 19.0 15.5
wt/wt ♂x wt/− ♀ 52.0 28.0 26.0 24.0 26.0 16.0 13.5 11.0 13.5 12.0 12.5 13.0 12.5
Total 229.0 106.0 96.2 123.0 132.8 61.0 50.8 60.0 70.2 45.0 45.3 63.0 62.7
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Figure 1. Phenotypic characterization of Lonp1wt/− mice. (A) Average weight and length of the body of
heterozygous (het) (red line) and wild type (wt) (black line) mice. Measures started from the third week
of life and were repeated every week until the 12th week, then at 4, 6, 8, 12, 16 and 18 months. Length
was measured from nose to base of tail. Data are expressed as mean ± SEM of at least three different
animals. (B) Analysis of weight of different organs and tissues. Measurements were taken after the
organs explant in 2- and 8-months old mice. Data are expressed as mean ± SEM; n = 5 or more.
Since LONP1 binds to and is necessary for maintenance of mitochondrial DNA, we quantified the
amount of mitochondrial DNA (mtDNA) in some of the tissues described above in young and adult
mice (Figure 2C). The levels of mtDNA were similar in wt and het animals and changed considerably
on the basis of the tissue taken into account, with the highest levels in heart and the lowest in the colon.
We did not observe significant changes between young and adult mice.
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Figure 2. LONP1 protein expression and mtDNA amount in different tissues. (A) Representative
examples of LONP1 expression in colon from wt and het mice. (B) Relative protein level of LONP1 in
the indicated tissues from 2 and 8 months-old mice. Data are expressed as mean ± SEM; n = 7 or more.
* = p < 0.05 (C) Quantification of mtDNA in different organs and tissues from 2 and 8 months-old mice;
n = 3 or more. Data are expressed as mean ± SEM.
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3.4. Histological Characterization of Lonp1wt/− Mouse
Since LONP1 depletion has been associated with lower risk of developing colon cancer in mice,
and since its downregulation deeply alters morphology and functionality of colon cancer cells in vitro,
we decided to focus our attention on possible differences present in colon. We measured colon length,
a sign of inflammation, but no changes have been observed (not shown). Then, we analyzed the colon
from a histological point of view, but hematoxylin-eosin staining did not reveal gross differences between
wt and het animals (Figure S3). Conversely, the ultrastructure analysis of enterocytes from the same
samples showed an impairment of the structure of mitochondria, which appeared increased in number,
swollen and larger in heterozygous mice, with a lower complexity and less organized cristae (Figure 3A–G).
Quantitative analysis of mitochondrial area, a parameter associated with mitochondrial dimensions and
perimeter, confirmed that mitochondria from Lonp1wt/−mice were larger, while lower values of aspect ratio
and form factor correspond to objects that were, on average, longer and less circular (Figure 3G).
Figure 3. Ultrastructure analysis of mitochondria morphology of colon enterocytes of a wt and het
mouse. (A–F) Ultrastructural features of mouse colon epithelium. A,C,E: wt; B,D,F: het. L = lumen;
MV = microvilli; N = nucleus. (G) Analysis of mitochondrial size, perimeter, aspect ratio and form
factor. Wt n = 203, het n = 153. Data are expressed as mean ± SEM. **** p < 0.0001.
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3.5. LONP1 and TFAM Levels Are Lower in Het Embryos, and Lead to mtDNA Reduction and
Mitochondrial Impairment
In order to get more insights into the functional effects of Lonp1 haploinsufficiency, we analyzed
the expression of Lonp1 and the mitochondrial features of MEFs obtained from wt and Lonpwt/− mice.
MEFs were cultured up to 55 days, and we did not observe any difference in the growth rate
or number of replications between wt and het cells (Figure S4); cells showed a regular fibroblastic
morphology. When we looked at mitochondrial morphology and ultrastructure of these cells, we
observed that the organelles appeared mostly perinuclear in het MEFs, with isolated branches in
the periphery of the cells (Figure 4A,B). Then, we analyzed nucleoids, whose LONP1 represents a
component, within mitochondria through STED microscopy, and we observed a reduction in their
number normalized to mitochondrial area, as well as in their dimensions, if compared to wt cells
(Figure 4C–E). Mitochondrial DNA quantification by droplet digital PCR evidenced an average 44%
reduction in mtDNA copies/cell in heterozygous MEFs (Figure 4F). The ultrastructure analysis revealed
an increased number of mitochondria in heterozygous MEFs compared with wt, in a way similar to
that observed in enterocytes from Lonpwt/− mice (Figure 5A,B). Quantitative analysis indicated a slight
reduction in mitochondrial size and perimeter, without significant changes in aspect ratio and form
factor (Figure 5C). We also observed an average 40% reduction of LONP1 protein expression in het
MEFs; such reduction was also observed in heads from Lonpwt/− embryos, when compared to wt ones
(Figure 6A,B). As LONP1 is involved in the regulation of cellular TFAM levels, we also evaluated the
expression of this protein in the same samples. In a way similar to LONP1, TFAM showed a slight
(30%), significant reduction in MEFs and embryo heads (Figure 6B and S5), in agreement with the
reduction of mtDNA levels.
Next, we asked whether these alterations of mitochondria morphology could affect mitochondrial
functionality, by evaluating OCR and ECAR of wt and het cells. We first analyzed the energetic
competence of het MEFs by comparing their oxygen consumption rate and extracellular acidification
rate with those of wt cells. Cells were first analyzed when cultured in a glucose containing medium, and
then after culturing in glucose-free, galactose containing medium, which forces cells to use respiration
rather than glycolysis. Figure 7A shows OCR and ECAR curves. MEFs from Lonp1wt/− mice cultured
in glucose showed a reduced oxygen consumption rate than wt cells in any condition tested. Basal
and non-mitochondrial oxygen consumption were significantly lower in het cells, while maximal
respiration, despite lower than controls, did not reach statistical significance (Figure 7B). In galactose
medium, both wt and het cells displayed a significant increase (around 20%) in basal respiration if
compared to cells grown in glucose, and wt cells also showed a higher basal and non-mitochondrial
oxygen consumption in this condition. Maximal respiration was almost identical in cells grown in
glucose and galactose medium, either in the case of wt or het cells (Figure 7B). A similar pattern was
observed in extracellular acidification rate: wt MEFs displayed a higher ECAR than het ones, either in
glucose or galactose medium. Baseline OCR and ECAR were plotted as an energy map, showing that
wt MEFs are characterized by a more energetic phenotype than het MEFs, which were more quiescent
(Figure 7C).
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Figure 4. Imaging of mitochondrial and submitochondrial structures and mtDNA amount in embryonic
fibroblasts (MEFs). (A,B) Confocal images of mitochondrial network from wt and het MEFs stained
with anti-TOM20. A: wt; B: het. (Bars of larger panels are 1 µm; bars of smaller panels: 10 µm).
(C,D) Stimulated emission depletion (STED0 images of mitochondrial DNA from wt and het MEFs
stained with anti-TOM20 and anti-dsDNA. C: wt; D: het. (Bars of larger panels are 1 µm; bars of
smaller panels: 10 µm). (E) Analysis of the number and the dimensions of nucleoids. (F) Mitochondrial
DNA quantification of MEFs by droplet digital PCR. Data are expressed as mean ± SEM. * = p < 0.05,
** = p < 0.01, *** = p < 0.0001.
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Figure 5. Ultrastructure analysis of mitochondria morphology of MEFs of wt and het mouse. Electron
microscopy images of MEFs from wt (A) and het mouse (B). (C) Analysis of mitochondrial size,
perimeter, aspect ratio and form factor. Wt n = 68, Het n = 192. Data are expressed as mean ± SEM.
*** p < 0.001.
We wondered if the reduction of OCR we observed in het cells was due to an impairment of
respiratory chain complexes. Thus, we measured complex expression levels in MEFs (Figure 7D).
All complexes were detectable in het MEFs and displayed a similar reduction in comparison with wt
cells. Such reduction proved significant in the case of CII, CIII and CV (Figure 7D). We also analyzed
the expression of ACO2, which is a substrate of LONP1 and of Grp75, which has been shown to interact
with LONP1 (Figure S6) and we did not observe any significant change.
Since mitochondria from het cells displayed an aberrant morphology and a reduction in OCR, we
wondered if this alteration could impact on mitochondrial membrane potential (MMP) and reactive
oxygen species production. Thus, we measured MMP and mtO2- levels by flow cytometry, using the
MMP-sensitive probe TMRM, and mitoSOX Red, respectively. No variations were observed in both
parameters in het cells, when compared to wild type ones (Figure 7E,F). No significant change was
also observed in the expression of the superoxide dismutase SOD2 (Figure S6). Cells were also tested
for mtO2− production in the presence of a stressor such as H2O2 2 mM for 30′. As expected, both wt
and het cells displayed an increase in mtO2− levels, but no differences were present between them
(not shown).
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Figure 6. LONP1 and TFAM protein expression in heads of embryos and in MEFs. (A) Western blot
analysis of LONP1 expression in heads of embryos and in MEFs. (B) Relative protein level of LONP1
and TFAM in heads of embryos and in MEFs. n = 3 or more. Data are expressed as mean ± SEM.
* p < 0.05.
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Figure 7. Analysis of mitochondrial functionality in wt and het cells. (A) Oxygen consumption rate
(OCR) and extracellular acidification rate (ECAR) curves from the analysis of wt (blue and red) and het
(green and purple) MEFs, obtained after the sequential addition of the indicated molecules. Data are
expressed as mean ± SEM of three independent analyses. (B) Parameters of respiration in wt and het
MEFs: basal respiration (left panel), maximal respiration, (central panel) and non-mitochondrial oxygen
consumption (right panel). Data are expressed as mean ± SEM of three independent experiments.
(C) Graph depicting OCR vs ECAR of wt and het cells grown in glucose or galactose. Data are expressed
as mean ± SEM of three independent experiments. (D) Relative expression of mitochondrial respiratory
complexes, as determined by western blot. Data are expressed as mean ± SEM of three independent
experiments. (E,F) Quantification of mitochondrial membrane potential by tetramethyl-rhodamine,
methyl ester (TMRM) and of anion superoxide by MTX. The net median fluorescence intensity (MFI)
value of a wt sample was set to 100 and other samples were determined as relative MFI levels according
to the formula: (het sample net MFI/wt sample net MFI) × 100. n = 3. Data are expressed as mean ±
SEM. * = p < 0.05..
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4. Discussion
In this study we described the phenotypic and molecular characterization of a heterozygous
mouse model for the protease LONP1. We confirmed the embryonic lethality of the total depletion
of Lonp1, as previously described [32] and this result is in agreement with the observation that the
silencing of LONP1 resulted in cell death in vitro [8]. Accordingly, the numbers of wt and het litters
reflect the expected Mendelian ratio we should observe in the presence of the embryonic lethality of
homozygous animals. To date, no absence of LONP1 has been described in living humans, indirectly
confirming that LONP1 is essential for cell functions. Mutations of this gene that partially alter its
functionality cause CODAS syndrome, but the pathogenetic mechanisms that links genetic defect
and phenotype has not been identified yet [36,39]. Conversely, het mice appear healthy, and we
did not detect any gross phenotypic, nor histological alterations which could suggest the presence
of inflammatory status or functional alterations of muscles, bones, nervous system and digestive
tract. This is in agreement with previous studies performed on another Lonpwt/− mouse model [32,42]
and with that observed in the parents of CODAS-affected patients, who appear healthy and without
relevant phenotypic alterations, despite the mutation in one copy of LONP1 [36,39,45].
When we analyzed Lonp1 expression in wt and het mice, we observed a remarkable tissue
variability. Few studies in the past have analyzed the expression of LONP1 in different tissue, and
mostly at the mRNA levels. High levels of LONP1 mRNA have been observed in the liver, brain, heart,
skeletal muscle, and lower but clearly detectable levels in lung, kidney and pancreas. Our data showed
that, as expected, Lonp1 is highly expressed in energy-demanding, mitochondrial-dependent tissues
like skeletal muscles and, to a minor extent, the liver, with the remarkable exception of colon, in which
LONP1 level increases during aging. LONP1 expression has been reported in the past to undergo
a progressive expression decline with aging; however, this is true only for some muscles, while the
liver does not show any significant variation, and heart levels even increased in very old animals [46].
Thus, our data further confirm that LONP1 expression over time does not follow a general trend but is
tissue specific.
In most of the analyzed tissues, the het mouse expresses approximately the same amount of
LONP1 protein as wt, suggesting the existence of a compensatory mechanism in the intact allele.
Preliminary observations in liver, skeletal muscle and colon indicate that mRNA levels of LONP1
are increased in het mice (not shown), suggesting that this phenomenon could indeed occur. LONP1
has been shown to be upregulated by stressors like heat shock or reactive oxygen species in several
models [14,19,47]. It is possible that adaptations to altered oxidative processes in mitochondria, present
when just a copy of Lonp1 gene is functional, leads to the upregulation of the gene that (partially)
compensates for the absence of one copy of the gene. Since we did not observe a higher level of
mtO2− in het MEFs, it is possible that other Lonp1-upregulating stimuli, such as proteotoxic stress,
could determine a partial increase in Lonp1 expression. The recent finding that the mt proteome
of Lonp1wt/− MEFs obtained in another Lonp1wt/− mouse model is characterized by upregulations of
pathways involved in oxidative stress and glutathione [43] is in agreement with our observation.
The only two exceptions are represented by the colon and heart of adult mice, which show a significant
reduction of LONP1 protein amount of approximately 50%. This is consistent with the observation of
Venkatesh et al. that described a reduction of 50–60% of LONP1 level in the heart [42].
As LONP1 downregulation is associated with altered functionality and morphology of colon
cancer cells in vitro and with lower risk of developing colon cancer in mice, we decided to analyze
possible differences present in the colon. In particular, mitochondria of enterocytes appeared increased
in number, swollen and with altered shape. Such dramatic morphological alterations are likely a
direct consequence of a reduced capability of mitochondria of Lonp1wt/− cells to maintain protein
homeostasis in the organelle. Indeed, our previous studies in cellular models of colorectal origin
demonstrated that LONP1 silencing or pharmacological inhibition determine a severe impairment of
mitochondrial proteome, leading to modification of proteins involved in stress response, energetic
metabolism and respiratory chain assembly with crucial effects on mitochondrial morphology and
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functionality [8,48]. It is interesting to note that these effects are tissue and cell specific, as in cellular
models of different origin it is greatly attenuated, and can be observed only after 10 days of LONP1
silencing [49]. Thus, it is not surprising that mitochondria of Lonpwt/− MEFs are increased in number
and present morphological alterations, but in a less dramatic way than those of Lonpwt/− enterocytes.
In MEFs, we have also found a reduction of LONP1 and of TFAM levels, in agreement with the
fact that LONP1 modulates its amount, and a reduction in the amount of mtDNA and nucleoids.
In their work, Quiros et al. reported that a decrease in mtDNA copy number could be observed only in
LONP1-deficient embryos, while heterozygous embryos did not show significant differences from
controls [32]. This discrepancy is likely due to the fact that the reduction of the mtDNA content needs
a rather long period of time to take place. Indeed, no reduction of mtDNA levels can be observed in
in vitro models after downregulating LONP1 to 20% of normal levels for more than 72 h [8]. Our data
strengthen the idea that even if LONP1 is essential for mtDNA maintenance, a small amount of the
protein is sufficient to maintain, at least partially, mtDNA copy levels in the cell for long periods.
From the functional point of view, MEFs from Lonpwt/− animals are characterized by reduced
respiration capacity. Such reduction is likely mediated by a reduced presence of respiratory complexes
and is in perfect agreement with what has been previously observed in different cellular models, in
which LONP1 silencing determined a dramatic reduction in respiratory capacity, accompanied by
an impairment in respiratory complex formation [8,30,49]. Recent, still unpublished data obtained
in a conditional knock out model of Lonp1 mouse showed decreased activity of the CI, CIII, CIV in
heart tissue, further confirming that LONP1 is necessary to maintain respiratory complex functionality.
However, the description of a patient with a biallelic mutation of LONP1 with a reduced pyruvate
dehydrogenase (PDH) activity and elevated intracellular lactate: pyruvate ratio suggests that the
alteration of cellular metabolism in LONP1 deficient cells could also be due to mechanisms not
directly related to OXPHOS impairment [41]. Since in MEFs from het mice we observed not only an
impairment in respiration, but also a lower acidification rate than wt cells, we can speculate that a
general decreased metabolism characterizes cells MEFs from het mice, and not a simple OXPHOS
reduction. This metabolic re-modelling might be the basis of the lack of proliferative capacity of cells
with a reduced expression of Lonp1 when a tumor develops.
The decrease of basal respiration could be a consequence of the decrease of non-mitochondrial
respiration but could be also correlated to a minor request of ATP, consequence of the quiescent
energetic phenotype showed by het MEFs. In our model, the absence of differences observed in
maximal respiration could be correlated with a different method used by cells to answer the deficiency
of glucose. The cause has not been examined in this study, but it has been shown that different cell
lines have different adaption to galactose medium, including intensification of the synthesis of Electron
transport chain (ETC) complexes, and in increase in mitochondrial biogenesis, in the use of glutamine
and in processing enzyme, or a combination of each [50].
In conclusion, data from this study, and from the morphological and functional alterations
observed in cells from patients with mutated LONP1, indicate that a reduced function of LONP1
is sufficient to impair mitochondrial ultrastructure and functions in vivo; this reduction can be the
consequence either of a lower expression of the wild type protein, or of a normal expression of a
partially functioning protein. In the presence of a mutation that partially reduces function, the effects
of mitochondria become evident only when both alleles are mutated, while the mutation of just one
allele, such as in parents of CODAS patients, is not sufficient to determine an effect.
We are well aware that our model does not allow us to identify which, among multiple functions
of LONP1, is the one that determines mitochondrial alterations when partially impaired. Further
studies with a Lonp1 mouse model bearing a point mutation ablating proteolytic activity are ongoing
to better clarify this point.
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